Focus: Arsenal Biosciences is a public biotechnology company headquartered in South San Francisco focused on cancer immunotherapy and oncology treatments. The company operates at an early clinical stage with a modest pipeline in Phase 1/2 development.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Recent layoff filing — 58 affected
Source: state DOL filings via Big Local News
Arsenal is a high-risk, early-stage oncology biotech with public-company infrastructure but deteriorating headcount signals; suitable only for risk-tolerant scientists seeking early clinical exposure, not career stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Arsenal Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Arsenal Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Substantial layoff signals and public WARN filings create material employment risk; company trajectory is negative regardless of pipeline potential.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo